Regnum (Regnum) Long-Term Debt : $0.00 Mil (As of Mar. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Regnum Long-Term Debt?

Regnum's Long-Term Debt for the quarter that ended in Mar. 2023 was $0.00 Mil.

Regnum Long-Term Debt Historical Data

The historical data trend for Regnum's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regnum Long-Term Debt Chart

Regnum Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Long-Term Debt

Get a 7-Day Free Trial

Regnum Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Long-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

Regnum (OTCPK:RGMP) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Regnum Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Regnum's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Regnum (Regnum) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regnum Corp (OTCPK:RGMP) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

600 Third Avenue, 19th Floor, New York, NY, USA, 10016

Website

https://www.regnumcorp.com

Regnum Corp is focused on developing and commercializing therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a CCR5 antagonist to treat multi-drug resistant HIV infection.

Regnum (Regnum) Headlines

No Headlines